Give Your Input on Impact of EU Clinical Trials Directive
ICREL allows you the opportunity to give your input through a survey about the EU Clinical Trials Directive.
Brussels, Belgium-June 9, 2008-ICREL is a one-year EU FP7 project, coordinated by EFGCP with further consortium members being EORTC under leadership of Denis Lacombe, ECRIN under leadership of Jacques Demotes, The Ethics Committee of the University of Vienna under leadership of Christiane Druml, and Hospital Clinic I de Barcelona under leadership of Xavier Carné. The project aims at analyzing the impact of the Clinical Trials Directive 2001/20/EC on clinical research in Europe.
ICREL has just launched a survey, giving sampled-out stakeholders (commercial and non-commercial sponsors, ethics committees, and competent authorities) the opportunity to have their experiences taken into account. As the results of this survey will form the basis for the European Commission Directorate Entreprise for their decisions on areas to be changed in the new clinical trials legislation it is very important that we collect as much information as possible. WE NEED YOUR SUPPORT!!!!
Please go to www.eortc.be/icrel and complete the questionnaire suitable for your type of organization.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
